Streetbeat News

Earnings

NSTG

NanoString Technologies has revised its FY23 revenue guidance from $175M-$185M to $175M-$180M, lower than the estimated $180.93M. The company also adjusted its spatial biology revenue from $100-$105M to $96-$100M, and its nCounter revenue from $75-$80M to $79-$80M. The projected EBITDA loss has increased from $65-$75M to $80-$85M.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 10:32 pm

PARR

Par Pacific Hldgs (NYSE:PARR) reported Q3 2023 earnings of $3.15 per share, in line with analyst estimates, and a 9.38% increase from the same period last year. The company's quarterly sales of $2.58 billion beat the analyst consensus estimate of $2.26 billion by 14.12%, marking a 25.42% increase from the previous year.

Portfolio Pulse from vinayak@benzinga.com

November 06, 2023 | 10:31 pm

QTRX

Quanterix reported Q3 earnings per share of $(0.21), beating the analyst consensus estimate of $(0.37) by 43.24%. This is a 44.74% increase over the same period last year. The company also reported quarterly sales of $31.33 million, beating the analyst consensus estimate of $27.59 million by 13.57%. This is a 17.59% increase over the same period last year.

Portfolio Pulse from mahesh@benzinga.com

November 06, 2023 | 10:30 pm

CE

Celanese Corporation (CE) has projected its Q4 adjusted EPS to be between $2.10 and $2.50. The company also expects its full-year adjusted EPS to be at the lower end of the $9-$10 range.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 10:30 pm

SGC

Superior Group of Companies has updated its FY23 outlook, forecasting a sales range of $538 million to $545 million, down from its earlier forecast of $550 million to $560 million. The company also adjusted its earnings per share forecast to a range of $0.46 to $0.53, compared to its earlier forecast of $0.45 to $0.55.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 10:29 pm

CE

Celanese (NYSE:CE) reported Q3 earnings of $2.50 per share, beating the analyst consensus estimate of $2.23 by 12.11%. However, this is a 36.55% decrease from the same period last year. The company's quarterly sales of $2.72 billion missed the analyst consensus estimate of $2.77 billion by 1.70%, but it's an 18.34% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 10:28 pm

RVMD

Revolution Medicines has updated its projected full year 2023 GAAP net loss to be between $385M-$415M, including an estimated non-cash stock-based compensation expense of $45M-$50M. The company's current cash, cash equivalents and investments are expected to fund operations into 2025. The financial guidance excludes the impact of the proposed EQRx transaction.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 10:27 pm

RHP

Ryman Hospitality Props (NYSE:RHP) reported Q3 earnings of $1.73 per share, a 0.58% increase YoY. However, the company's quarterly sales of $528.51M missed the analyst consensus estimate of $530.47M by 0.37%. The sales figure represents a 12.99% increase YoY.

Portfolio Pulse from mahesh@benzinga.com

November 06, 2023 | 10:27 pm

RHP

Ryman Hospitality Properties forecasts an 11.5%-12.5% growth in FY23 Consolidated Hospitality Total RevPAR.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 10:26 pm

NEO

NeoGenomics reported Q3 2023 sales of $151.95 million, beating the analyst consensus estimate of $142.00 million by 7.01 percent. This represents a 17.99 percent increase over the same period last year.

Portfolio Pulse from vinayak@benzinga.com

November 06, 2023 | 10:26 pm